Abstract
Background: Colorectal cancer (CRC) is a kind of tumor with high incidence and its treatment situation is still very difficult despite the constant renewal and development of treatment methods.
Objective: To assist the prognosis, monitoring and survival of CRC patients with a model.
Methods: In this study, we established a new prognostic model for CRC. Four groups of CRC data were accessed from the GEO database, and then differential analysis (logFoldChange>1, adjust- P<0.05) was carried out by using the limma package along with the RobustRankAggreg package used to identify the overlapping differentially expressed genes (DEGs). Univariate and multivariate Cox regression analyses were performed on the DEGs to screen the genes related to the patient’s prognosis, and a five-gene prognostic prediction model (including RPX, CXCL13, MMP10, FABP4 and CLDN23) was constructed. Then, we further plotted ROC curves to evaluate the predictive performance of the five-gene prognostic signature in the TCGA data sets (the AUC values of 1, 3, 5-year survival were 0.68, 0.632, 0.675, respectively) and an external independent data set GSE2962 (the AUC values of 1, 3, 5-year survival were 0.689, 0.702, 0.631, respectively).
Results: The results showed that the model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Conclusion: The model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Keywords: Prognosis, signature, CRC, predictive, CLDN23, FABP4, MMP10, CXCL13.
Current Gene Therapy
Title:A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Volume: 21 Issue: 4
Author(s): Junfeng Hong, Xiangwu Lin, Xinyu Hu, Xiaolong Wu and Wenzheng Fang*
Affiliation:
- Department of Oncology, Fuzhou General Hospital of Fujian Medical University, East Hospital Affiliated to Xiamen University (the 900th Hospital of The Joint Logistics Support Force of Chinese PLA), Dongfang Hospital, Xiamen University, Fuzhou, Fujian, 350025,China
Keywords: Prognosis, signature, CRC, predictive, CLDN23, FABP4, MMP10, CXCL13.
Abstract:
Background: Colorectal cancer (CRC) is a kind of tumor with high incidence and its treatment situation is still very difficult despite the constant renewal and development of treatment methods.
Objective: To assist the prognosis, monitoring and survival of CRC patients with a model.
Methods: In this study, we established a new prognostic model for CRC. Four groups of CRC data were accessed from the GEO database, and then differential analysis (logFoldChange>1, adjust- P<0.05) was carried out by using the limma package along with the RobustRankAggreg package used to identify the overlapping differentially expressed genes (DEGs). Univariate and multivariate Cox regression analyses were performed on the DEGs to screen the genes related to the patient’s prognosis, and a five-gene prognostic prediction model (including RPX, CXCL13, MMP10, FABP4 and CLDN23) was constructed. Then, we further plotted ROC curves to evaluate the predictive performance of the five-gene prognostic signature in the TCGA data sets (the AUC values of 1, 3, 5-year survival were 0.68, 0.632, 0.675, respectively) and an external independent data set GSE2962 (the AUC values of 1, 3, 5-year survival were 0.689, 0.702, 0.631, respectively).
Results: The results showed that the model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Conclusion: The model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Export Options
About this article
Cite this article as:
Hong Junfeng , Lin Xiangwu , Hu Xinyu , Wu Xiaolong and Fang Wenzheng*, A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer, Current Gene Therapy 2021; 21 (4) . https://dx.doi.org/10.2174/1566523220666201012151803
DOI https://dx.doi.org/10.2174/1566523220666201012151803 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment Strategies for Cervical Cancer in Older Women: Challenges and
Advancements
Current Cancer Therapy Reviews Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review
Current Radiopharmaceuticals Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer
Current Cancer Drug Targets β-Glucuronidase Inhibitory Studies on Coumarin Derivatives
Medicinal Chemistry FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Multidetector Computed Tomography of Iatrogenic Urinary Trauma - Pictorial Review
Current Medical Imaging Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Antimicrobial Photosensitizers: Drug Discovery Under the Spotlight
Current Medicinal Chemistry The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status
Current Medicinal Chemistry Purinergic Signaling and its Role in the Stem Cell Differentiation
Mini-Reviews in Medicinal Chemistry Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer
Current Drug Targets